Africa Day at Novartis highlights the continent’s healthcare needs and efforts to address them.
Of 100 companies analyzed, Novartis ranked #18 across all industries, #4 in the healthcare sector and #1 in Switzerland. Learn more about environmental protection efforts at Novartis.
Ann Aerts has stared death in the eye. The head of the non-profit Novartis Foundation lost colleagues when she was serving as an emergency medicine physician on a medical mission in a dangerously unstable country.
The head of Public Affairs for the Novartis Malaria Initiative has a malaria story of her own to tell.
Today, many companies are trying to solve global health challenges through philanthropy. However, it has become clear that philanthropy alone is no longer enough to make a lasting impact.
The incidence of leprosy, an infectious disease that causes lumps and skin sores, has decreased by roughly 95%, but 233,000 new cases were reported in 2012.
Professor Klaus M. Leisinger is stepping down as Chairman of the Board of the Novartis Foundation for Sustainable Development (NFSD). Dr. Andrin Oswald will take on an additional role as Chairman of the Board overseeing the NFSD.
Malaria programs in sub-Saharan Africa are making progress by using insecticide-treated nets, diagnostic testing and Artemisinin-based Combination Therapy.
Review the strategy and annual performance of Novartis and read letters from our Chairman and CEO.
This site is intended for a global audience.